LDLR Genetic Test: Familial Hypercholesterolemia Risk and Results

An LDLR genetic test looks for disease-causing variants in the gene that makes the low-density lipoprotein receptor. This receptor removes LDL cholesterol from the bloodstream. When one copy of LDLR does not work properly, LDL cholesterol can remain high from childhood and cause heterozygous familial hypercholesterolemia. When both copies are severely affected, homozygous familial hypercholesterolemia can cause extremely high LDL levels and cardiovascular disease very early in life. A positive result can confirm a molecular diagnosis, support earlier and more intensive cholesterol treatment, and allow relatives to receive targeted testing. It does not replace a lipid panel or cardiovascular assessment, and a negative result does not exclude familial hypercholesterolemia. LDLR findings also vary in severity: some variants leave partial receptor activity, while others produce little or none. Accurate interpretation therefore depends on the exact variant, untreated LDL cholesterol, physical findings, family history, and whether other genes such as APOB, PCSK9, or LDLRAP1 were examined.

• A pathogenic or likely pathogenic LDLR variant can confirm a genetic cause of familial hypercholesterolemia when the cholesterol pattern fits.
• One affected LDLR copy usually causes heterozygous FH; two disease-causing variants can cause much more severe homozygous or compound-heterozygous FH.
• LDL cholesterol may be very high for decades before symptoms appear, so a normal physical examination does not rule out FH.
• A negative LDLR test does not exclude FH because other genes, polygenic cholesterol risk, and undetected variants can produce a similar phenotype.
• A variant of uncertain significance should not be used alone to diagnose relatives or determine treatment intensity.
• Chest pressure, sudden shortness of breath, fainting, or stroke symptoms require emergency evaluation regardless of the genetic result.

Table of Contents

• What LDLR testing measures
• Who should consider an LDLR test
• How the test is performed
• Interpreting positive, negative, and uncertain results
• Heterozygous and homozygous familial hypercholesterolemia
• How LDLR results guide treatment
• Cascade testing for relatives
• Next steps after the result

What LDLR testing measures

The LDLR gene provides instructions for the LDL receptor, a protein concentrated on the surface of liver cells. LDL particles bind to the receptor and are pulled out of circulation. The receptor then returns to the cell surface and can be reused. This process is one of the body’s main ways of controlling LDL cholesterol.

A disease-causing LDLR variant can disrupt the process at several stages. The receptor may not be made, may not reach the cell surface, may fail to bind LDL, may not bring LDL into the cell, or may not recycle normally. Variants are sometimes grouped by residual function, although routine reports do not always provide a precise percentage of activity.

Familial hypercholesterolemia, or FH, is a lifelong disorder of LDL exposure. The danger comes from cumulative exposure rather than a single test result. A person whose LDL has been high since childhood has more “cholesterol-years” than someone whose LDL rose later because of age, diet, thyroid disease, or medication.

Most molecularly confirmed FH involves LDLR. Other established causes include:

• Pathogenic variants in APOB that weaken the binding of LDL particles to the LDL receptor
• Gain-of-function variants in PCSK9 that increase receptor breakdown
• Biallelic LDLRAP1 variants that impair internalization of the LDL-receptor complex

This overlap is why a familial hypercholesterolemia gene panel is often preferable to LDLR-only testing when no familial variant is known. A targeted LDLR test is ideal when the exact disease-causing change has already been identified in the family.

The genetic test is different from measuring LDL cholesterol. DNA usually remains constant throughout life, while LDL levels change with age, illness, diet, pregnancy, weight, and medication. A genetic result identifies an inherited mechanism; the lipid panel shows the current biochemical effect.

Who should consider an LDLR test

Testing is most useful when clinical findings suggest FH or when a pathogenic LDLR variant is already known in a relative. Clinical diagnosis can be made without genetic confirmation, but a molecular result often improves family detection and can strengthen the case for early, intensive treatment.

Features that raise suspicion include:

• Untreated LDL cholesterol of 190 mg/dL or higher in an adult
• Untreated LDL cholesterol around 160 mg/dL or higher in a child, especially with a family history
• LDL levels above the 95th percentile for age and sex on repeated tests
• Coronary artery disease, heart attack, or coronary procedures at an unusually young age
• A parent, sibling, or child with very high LDL or premature atherosclerotic cardiovascular disease
• Tendon xanthomas, particularly thickening over the Achilles tendon or extensor tendons of the hands
• Corneal arcus at a young age
• Very high LDL in both parents or severe hypercholesterolemia in a young child

These thresholds are clues rather than stand-alone rules. Secondary causes should be assessed, including hypothyroidism, nephrotic syndrome, cholestatic liver disease, uncontrolled diabetes, and certain medicines. Secondary disease can coexist with FH and push LDL even higher.

Clinical tools such as the Dutch Lipid Clinic Network criteria, Simon Broome criteria, and MEDPED criteria combine LDL level, family history, physical findings, and personal cardiovascular history. They can estimate whether FH is definite, probable, or possible. Genetic testing can confirm many, but not all, clinically suspected cases.

The probability of a positive test rises with the strength of the phenotype. An adult with untreated LDL above 250 mg/dL, tendon xanthomas, and a parent who had a heart attack at 42 is more likely to have monogenic FH than an adult with LDL of 195 mg/dL and no family history. The second person may still have FH, especially if the family history is incomplete.

Children of a parent with molecularly confirmed FH are strong candidates for targeted testing. Early identification allows treatment before substantial arterial plaque develops. Testing a healthy child for an adult-onset condition can raise ethical concerns, but FH is actionable during childhood, so pediatric testing is generally supported.

How the test is performed

The laboratory usually analyzes DNA from blood or saliva. Fasting is unnecessary for the genetic sample, and cholesterol-lowering medicines do not affect the DNA result. A separate lipid panel may require preparation according to the clinician’s instructions, although nonfasting lipid testing is acceptable in many settings.

Testing can take several forms:

1. Targeted familial-variant testing: The laboratory looks only for the exact LDLR change previously found in a relative.
2. LDLR sequencing: The coding regions and nearby splice boundaries are examined for single-letter changes and small insertions or deletions.
3. Deletion and duplication analysis: The test looks for missing or extra exons or larger segments that sequencing may miss.
4. FH multigene panel: LDLR is tested with APOB, PCSK9, LDLRAP1, and sometimes additional genes that cause overlapping lipid disorders.
5. Broader sequencing: Exome or genome analysis may be considered when the phenotype is severe and panel testing is unrevealing.

A good order includes both sequencing and deletion/duplication detection unless the laboratory can show that its method captures both. LDLR has thousands of reported variants, including missense, nonsense, splice, frameshift, and copy-number changes.

Pretest counseling should review the possible result categories, family implications, insurance questions, and the limits of testing. A pathogenic result may reveal that relatives have a 50% inheritance risk. It may also uncover two variants, raising concern for severe FH, or identify an unexpected relationship within the family.

The laboratory should use disease-specific interpretation standards. General variant rules are important, but LDLR has well-developed ClinGen specifications that account for receptor function, LDL levels, family segregation, population frequency, and established functional assays. Disease-specific curation reduces inconsistent classification across laboratories.

Turnaround time commonly ranges from a few weeks to several months. Testing a known familial variant is usually faster and less expensive than analyzing a full panel. Insurance coverage varies and may depend on documented LDL values, clinical criteria, or a known result in a first-degree relative.

Interpreting positive, negative, and uncertain results

Genetic reports classify variants according to the strength of evidence. The classification, not merely the presence of a DNA difference, determines clinical use.

Result	Usual interpretation	Appropriate response
Pathogenic or likely pathogenic	Strong evidence that the variant impairs LDL receptor function and causes FH.	Combine with the lipid phenotype, intensify prevention as needed, and offer targeted testing to relatives.
Variant of uncertain significance	Evidence is insufficient or conflicting.	Do not use it alone for diagnosis, predictive family testing, or medication authorization; request periodic reinterpretation.
Negative	No reportable LDLR variant was detected by the assay.	Continue clinical management based on LDL and risk; consider a broader panel or polygenic explanation.
Benign or likely benign	The variant is not considered a cause of FH.	Do not use it to explain high LDL or test relatives.

A positive result in one LDLR copy usually supports heterozygous FH. It does not establish the person’s current cardiovascular status. Coronary plaque, symptoms, blood pressure, smoking, diabetes, lipoprotein(a), and years of untreated LDL exposure all modify risk.

The exact variant can influence average severity. A receptor-negative variant that leaves little or no function often produces higher untreated LDL than a receptor-defective variant with partial activity. However, LDL levels overlap, and treatment should respond to the measured phenotype rather than a variant label alone.

A negative result does not erase a strong clinical diagnosis. Standard panels do not detect every regulatory, deep-intronic, structural, or mosaic variant. The person may carry a pathogenic variant in another gene or have a high burden of common LDL-raising variants. Polygenic hypercholesterolemia can resemble FH in one person but usually produces less clear autosomal dominant transmission across a family.

A VUS requires restraint. Testing relatives may sometimes help the laboratory study whether the variant tracks with high LDL, but it should not be used as routine predictive testing. A healthy relative who carries a VUS has not been proven to have FH, and a relative who lacks it has not been cleared of lipid risk. The same careful rules apply to any variant of uncertain significance.

If two pathogenic variants are reported, the laboratory should determine whether they are in trans, meaning on opposite chromosome copies, or in cis, meaning on the same copy. Parental testing may resolve this. Two variants in trans can support biallelic FH and may predict a more severe phenotype.

Heterozygous and homozygous familial hypercholesterolemia

Heterozygous FH, abbreviated HeFH, usually results from one pathogenic variant in LDLR, APOB, or PCSK9. It affects roughly one person in a few hundred in many populations. Untreated LDL is often 190 to 400 mg/dL in adults, though values vary and overlap with other conditions.

Homozygous FH, or HoFH, is much rarer and usually results from two severe variants affecting the LDL-receptor pathway. The variants may be identical, different changes in the same gene, or changes in two different FH genes. The term “homozygous” is often used clinically for the severe biallelic phenotype even when the precise genotype is compound heterozygous.

HoFH should be considered when:

• Untreated LDL cholesterol exceeds about 400 mg/dL
• Xanthomas appear in childhood
• Both parents have FH or very high LDL
• Aortic-root disease, coronary disease, or ischemic symptoms develop unusually early
• Standard medication produces a limited response

LDL level remains central because genotype and phenotype do not always align perfectly. Some people with two receptor-defective variants retain enough activity to have LDL below traditional HoFH thresholds. Others with one severe variant plus strong polygenic or metabolic factors may have very high levels.

Receptor activity affects treatment response. Statins and PCSK9 inhibitors depend partly on increasing or preserving functioning LDL receptors. They may work less well when receptor activity is nearly absent. Evinacumab lowers LDL through an LDL-receptor-independent pathway and can be useful in severe HoFH. Lomitapide and lipoprotein apheresis are additional specialist options in selected patients.

A child with suspected HoFH needs prompt referral to a lipid specialist. Waiting for adult thresholds or symptoms can allow rapid atherosclerosis to progress. Evaluation may include echocardiography for aortic-root and valve disease, vascular imaging, and early combination therapy.

How LDLR results guide treatment

Treatment aims to lower lifelong LDL exposure as early and as safely as possible. A genetic result can support urgency and family screening, but LDL targets and medication choices depend on the full risk profile.

Lifestyle measures remain valuable:

• Replace saturated and trans fats with unsaturated fats
• Emphasize vegetables, legumes, whole grains, nuts, and fiber-rich foods
• Maintain regular physical activity suitable for cardiovascular status
• Avoid smoking and secondhand smoke
• Manage blood pressure, diabetes, sleep, and body weight

Lifestyle alone rarely lowers LDL enough in monogenic FH because the receptor pathway is impaired. Medication is usually necessary.

For adults with HeFH, treatment often begins with a high-intensity statin unless contraindicated. Ezetimibe can be added when LDL reduction is insufficient. PCSK9 monoclonal antibodies or inclisiran may provide substantial additional lowering. Bempedoic acid is another option for selected adults, especially when statin intolerance limits therapy.

Children with HeFH often begin statin treatment in late childhood, commonly around ages 8 to 10, although timing depends on LDL severity, family history, and the specific medicine. Earlier therapy may be considered in severe cases. Growth, puberty, liver enzymes, muscle symptoms, and adherence should be monitored.

Treatment intensity increases when a person already has coronary artery disease, diabetes, chronic kidney disease, high lipoprotein(a), or a strong family history of early events. Measuring lipoprotein(a) at least once can identify an additional inherited risk factor that is common in FH families.

A positive LDLR result does not determine whether a specific drug will work perfectly. Receptor-negative variants may blunt response to therapies that rely heavily on LDLR activity, but measured LDL change after treatment is the decisive evidence. Clinicians typically repeat a lipid panel several weeks after starting or changing therapy and adjust the regimen accordingly.

HoFH usually requires several therapies at once and care at a specialized center. Lipoprotein apheresis physically removes LDL from the blood and may be performed every one to two weeks. Liver transplantation is rarely considered because it supplies functioning LDL receptors but carries major lifelong risks.

Cascade testing for relatives

Cascade testing starts with the closest biological relatives of a person with confirmed FH and expands through the family. It is one of the most effective ways to find people before a heart attack occurs.

When one pathogenic LDLR variant is present, each child and each full sibling generally has a 50% chance of carrying it. The affected person’s parents can be tested to identify which side of the family is at risk. A parent may appear healthy despite decades of high LDL, so absence of symptoms is not reassuring.

Targeted testing for the known variant is preferable to ordering a new broad panel in every relative. Relatives should also have a lipid profile because LDL severity guides treatment and can identify additional causes. A carrier with a modest LDL level still needs assessment; a noncarrier can have high cholesterol for unrelated reasons.

Children in an affected family can be tested once the familial variant is known. If genetic testing is not available, cholesterol screening should begin in childhood. A normal LDL result in a very young child may need confirmation later, especially if the family’s phenotype is mild.

A negative targeted test usually means the relative did not inherit that familial LDLR variant and does not have the associated 50% genetic risk. It does not guarantee lifelong normal cholesterol. Routine population-based lipid screening still applies.

Family letters can make communication easier. They should include the diagnosis, exact gene and variant, inheritance pattern, recommended testing, and clinic contact information. The proband should share the laboratory report rather than relying on memory or a phrase such as “the cholesterol gene.”

Why the result still matters after LDL falls

Successful treatment can bring LDL cholesterol into a much safer range, but it does not make the inherited variant disappear or erase the cholesterol exposure that occurred before treatment. The result remains relevant when clinicians estimate lifetime risk, decide how intensively to maintain therapy, and identify relatives who may still be untreated. A low on-treatment LDL should therefore not be mistaken for evidence that the original diagnosis was wrong.

When LDL remains above the agreed goal despite several medicines, the next step is not simply to blame the LDLR variant. The clinician should confirm adherence, dosing, and access; review secondary causes such as hypothyroidism, kidney disease, liver disease, and interacting medicines; and compare the observed response with the expected effect of each therapy. Markedly limited response, childhood xanthomas, or an extreme untreated LDL level should prompt reconsideration of biallelic disease and referral to a specialist center. The measured response guides treatment, while the genotype explains why lifelong follow-up and family screening remain necessary.

Next steps after the result

After receiving an LDLR report, schedule a review with the ordering clinician, lipid specialist, or genetic counselor. The visit should connect the genetic finding with untreated and treated LDL values, current cardiovascular risk, and a concrete family plan.

Useful questions include:

• Is the variant pathogenic, likely pathogenic, or uncertain under LDLR-specific criteria?
• Does the laboratory report residual receptor function or a receptor-negative versus receptor-defective mechanism?
• Was deletion and duplication analysis included?
• Should APOB, PCSK9, LDLRAP1, or other genes be tested?
• What LDL reduction and treatment target are appropriate for my age and cardiovascular history?
• Should I have coronary imaging, lipoprotein(a) testing, or evaluation for tendon xanthomas?
• Which relatives should be tested first?
• When should children in the family have genetic and lipid testing?
• How often will the laboratory review the variant classification?

Keep the full report and the earliest available untreated lipid results. Medication can lower LDL enough that the original phenotype becomes hard to reconstruct years later. Family history should be updated when relatives have new diagnoses or cardiovascular events.

Variant reinterpretation is important, particularly for a VUS. Laboratories may gain functional data, identify the variant in more families, or revise population-frequency evidence. A classification change can alter whether cascade testing is appropriate.

The diagnosis should never delay treatment while genetic testing is pending. A person with severe LDL elevation or established atherosclerotic disease needs clinical management based on current risk. Genetic testing adds precision, but prevention begins with recognizing and lowering the LDL burden.

References

• Familial Hypercholesterolemia 2025 (GeneReviews)
• The Clinical Genome Resource (ClinGen) Familial Hypercholesterolemia Variant Curation Expert Panel consensus guidelines for LDLR variant classification 2022 (Guideline)
• 2023 update on European Atherosclerosis Society consensus statement on homozygous familial hypercholesterolaemia: new treatments and clinical guidance 2023 (Consensus Statement)
• 2024 Polish recommendations for the management of familial hypercholesterolemia in children and adolescents 2024 (Guideline)
• The Importance of Genetic Testing for Familial Hypercholesterolemia 2024 (Review)
• The functional landscape of coding variation in the familial hypercholesterolemia gene LDLR 2025

Disclaimer

This article is educational and does not replace individualized care from a lipid specialist, cardiologist, pediatrician, or genetic counselor. Do not stop or change cholesterol medication based only on a genetic report or online information. New chest pressure, sudden shortness of breath, fainting, weakness on one side, or difficulty speaking requires emergency medical attention.